Understanding drugs in breast cancer through drug sensitivity screening

Next generation analysis of breast cancer genomes for precision medicine

(2013) Maurizio Previati et al.   CANCER LETTERS

Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition

(2013) R. Katayama et al.   CANCER RESEARCH

The emerging role of MET/HGF inhibitors in oncology

(2013) Giorgio V. Scagliotti et al.   CANCER TREATMENT REVIEWS

Serdemetan Antagonizes the Mdm2-HIF1α Axis Leading to Decreased Levels of Glycolytic Enzymes

(2013) Jason A. Lehman et al.   PLoS One

Cisplatin, oxaliplatin, and carboplatin unequally inhibit in vitro mRNA translation

(2013) Jonas Philipp Becker et al.   TOXICOLOGY LETTERS

A Water-Based Mechanism of Specificity and Resistance for Lapatinib with ErbB Family Kinases

(2012) Yulin Huang et al.   BIOCHEMISTRY

Next-generation sequencing in breast cancer

(2012) Christine Desmedt et al.   CURRENT OPINION IN ONCOLOGY

Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib

(2012) Kiana Keyvanjah et al.   Journal of Translational Medicine

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Reanalysis of RNA-Sequencing Data Reveals Several Additional Fusion Genes with Multiple Isoforms

(2012) Sara Kangaspeska et al.   PLoS One

PARP inhibitors – current status and the walk towards early breast cancer

(2011) Jennifer Glendenning et al.   BREAST

Despite steep costs, payments for new cancer drugs make economic sense

(2011) Frank R Lichtenberg   NATURE MEDICINE

Subtype and pathway specific responses to anticancer compounds in breast cancer

(2011) L. M. Heiser et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Four human breast cancer cell lines with biallelic inactivating α-catenin gene mutations

(2009) Antoinette Hollestelle et al.   BREAST CANCER RESEARCH AND TREATMENT

Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines

(2009) Antoinette Hollestelle et al.   BREAST CANCER RESEARCH AND TREATMENT

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

Cisplatin versus Cisplatin plus Doxorubicin for Standard-Risk Hepatoblastoma

(2009) Giorgio Perilongo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

(2008) Sanjeev Shangary et al.   Annual Review of Pharmacology and Toxicology

Nutlin-3a Activates p53 to Both Down-regulate Inhibitor of Growth 2 and Up-regulate mir-34a, mir-34b, and mir-34c Expression, and Induce Senescence

(2008) K. Kumamoto et al.   CANCER RESEARCH

Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma

(2008) H. Huynh et al.   CLINICAL CANCER RESEARCH

Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells

(2008) Anieta M. Sieuwerts et al.   JNCI-Journal of the National Cancer Institute